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In the current issue of Cancer Cell, Loizou et al. report that the deletion of ATM Interactor (ATMIN) in devel-
oping B cells leads to profound genomic instability and clonal B cell leukemia, revealing a novel tumor
suppressor function for ATMIN.Lymphocyte development requires or-
dered assembly of the antigen receptor
loci through V(D)J recombination. B lym-
phocytes also undergo additional gene
modifications—somatic hypermutation
(SHM) and class switch recombination
(CSR)—to achieve high affinity and
diverse effector functions (Nussenzweig
and Nussenzweig, 2010). V(D)J recombi-
nation and CSR both entail the formation
of DNA double strand breaks (DSBs) as
an obligate intermediate, invoke strong
DNA damage responses, and require effi-
cient DSB repair for completion (Gostissa
et al., 2011). In repair-deficient cells, unre-
paired DSBs generated during V(D)J
recombination and CSR often participate
in oncogenic chromosomal transloca-
tions that eventually lead to malignant
transformation, especially in the absence
of an appropriate checkpoint response
(Gostissa et al., 2011). Indeed, aberrant
resolution of these DSBs is likely respon-
sible for many of the recurrent chromo-
somal translocations characteristic of
human lymphoid malignancies (Nussenz-
weig and Nussenzweig, 2010).
The ATM kinase is a master regulator of
the DNA damage response. Physiological
DSBs generated during V(D)J recombina-
tion and CSR signal through the MRN
(MRE11-RAD50-NBS1) complex to acti-
vate ATM, which then phosphorylates
substrates involved in both DNA repair
and cell-cycle checkpoint control (Fig-
ure 1) (Lavin, 2008). Recent studies indi-
cate that the ATM kinase can also be
activated independent of DSBs, such as
under hypotonic conditions orwith chloro-
quine, although themolecular mechanism
and physiological significance of DSB-
independent ATM activation remain
unclear (Lavin, 2008). In human patients,homozygous inactivation of ATM causes
Ataxia Telangiectasia, a rare genetic syn-
drome associatedwith genomic instability
and predisposition to lymphoid malignan-
cies. Somatic inactivation of ATM has
been reported in many human cancers,
including a subset of B and T cell malig-
nancies (Boultwood, 2001).
The ATM Interactor (ATMIN, also called
ASCIZ) is a nuclear Zn2+ finger protein
with a C-terminal cluster of SQ/TQ motifs
that can be phosphorylated by ATM and
ATM-related kinases (Kanu and Behrens,
2007; McNees et al., 2005). ATMIN binds
to ATM under basal conditions and has
been proposed to regulate ATM activity
uponhypotonic stress (KanuandBehrens,
2007). In the current issue of Cancer Cell,
Loizou et al. (2011) report that inactivation
of ATMIN in developing B cells leads to
a 50% reduction in CSR. The CSR defects
in ATMIN-deficient B cells are accompa-
nied by general genomic instability as
well as antigen receptor locus-specific
breaks (Loizou et al., 2011). This pheno-
type is very similar, though less severe
than that described for ATM-deficient B
cells (Lavin, 2008). Moreover, up to 40%
of mice with B cell-specific deletion of
ATMIN developed B lymphoma within six
months (Loizou et al., 2011), revealing
a strong tumor suppressor function of
ATMIN.Whatdo theseobservations reveal
about the functions of ATMIN and its rela-
tionship to ATM?
Loizou et al. (2011) observed that focus
formation by activated ATM (p-S1987) is
reduced in ATMIN-deficient B cells, sug-
gesting suboptimal ATM activation. While
DSBs generated during CSR were
thought to be the primary signal for ATM
activation, Loizou et al. (2011) show that
ATM is activated normally in ATMIN-defi-Cancer Celcient B cells by DSBs but not by hypo-
tonic stress. Therefore, they propose
that DSB-independent activation of ATM
via ATMIN ensures robust ATM activity
for efficient DNA repair in switching B cells
(Figure 1). Although hypotonic stress was
proposed to activate ATM by altering
chromatin structure, the physiological
stimulus that triggers ATMIN-dependent
ATM activation in switching B cells re-
mains unclear. During both V(D)J recom-
bination and CSR, the formation of DSBs
by lymphocyte-specific factors (i.e., RAG
or AID) is accompanied by well-doc-
umented chromatin movements (e.g.,
looping, pairing) and histone modifica-
tions, which could potentially stimulate
ATMIN-dependent activation of ATM,
independent of DSBs (Gostissa et al.,
2011). In this context, ATMIN-deficient B
cells should provide a unique platform to
address the molecular mechanisms of
DSB-independent ATM activation in DNA
repair and tumor suppression. Curiously,
while ATMIN is required for ATM activa-
tion by hypotonic stress in B cells (Loizou
et al., 2011), studies on ATMIN-deficient
fibroblasts have yielded conflicting re-
sults, with one group observing profound
defects in hypotonic stress-induced
ATM activation (Kanu and Behrens, 2007),
and another group reporting no defects
(Jurado et al., 2010). Identifying the phys-
iological signal that triggers ATMIN-
dependent activation of ATM in B cells
may also help resolve this disparity.
Since ATMIN has multiple SQ/TQ motifs
(15–18,dependingonspecies)and isphos-
phorylated by ATM in vivo (McNees et al.,
2005), it could also function downstream
of ATM in DNA repair and checkpoint
control (Figure 1). ATMIN is recruited to
nuclear foci after methyl methanesulfonatel 19, May 17, 2011 ª2011 Elsevier Inc. 569
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Figure 1. ATMIN Is a Tumor Suppressor in Developing B Cells
B cell development requires sequential modifications of the antigen-receptor loci through V(D)J recombi-
nation and CSR. Both V(D)J recombination and CSR generate DNA DSBs and involve chromatin changes,
which activate ATM and lead to the phosphorylation of ATM substrates. ATMIN potentially contributes to
DNA repair and checkpoint control in developing B cells (I) as an activator of ATM in response to chromatin
changes, (II) as a substrate of ATM, and (III) as independent of ATM. Together, ATMIN deficiency leads to
genomic instability and B cell lymphomas.
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Previews(MMS) treatment, and ATMIN-deficient
cells display hypersensitivity to H2O2 and
MMS, reduced RAD51-focus formation,
and defects in base excision repair (Jurado
et al., 2010; KanuandBehrens, 2007; Kanu
et al., 2010;McNees et al., 2005). Nonethe-
less, it is still unclear whether ATM phos-
phorylation of ATMIN plays a role in these
processes. Interestingly, unlike other ATM
substrates (e.g., H2AX), ATMIN is signifi-
cantly phosphorylated under basal condi-
tions (McNees et al., 2005), though the
functions of basal ATMIN phosphorylation
are not known. In addition, ATMIN may
also participate in the DNA damage
response indirectly through interaction
with other ATM substrates, such as CHK2
(McNees et al., 2005).
Although ATM null mice are viable
(Lavin, 2008), ATMIN null mice are embry-
onic lethal with severe pulmonary devel-
opmental defects (Jurado et al., 2010;
Kanu et al., 2010). As such, ATMIN clearly
has ATM-independent functions (Fig-
ure 1), some of which may potentially
contribute to tumor suppression. Despite570 Cancer Cell 19, May 17, 2011 ª2011 Elsless severe CSR defects, more than
40% of mice with B cell specific deletion
of ATMIN succumbed to B cell lym-
phomas within a year (Loizou et al.,
2011), while germline ATM null mice
succumb to T cell lymphomas between
3 and 9 months, with no documented B
cell tumors (Lavin, 2008). Mice carrying
a hypomorphic ATM mutation (equivalent
to 7636del9 in human) do develop B cell
malignancies but with a long latency
(>40 weeks) and low penetrance (3 out
of 40). Why ATMIN deficiency seemly
promotes B cell lymphomas in mice
more efficiently than does ATM deficiency
is unknown and of considerable interest.
In particular, human patients with germ-
line ATM mutations do develop B cell
lymphomas. Notably, ATMIN-deficient B
cell lymphomas display diverse surface
phenotypes, ranging from those of early
native B cell to those of plasma cells,
and have various chromosomal translo-
cations, most of which do not involve
immunoglobulin loci. Molecular charac-
terization of the translocation junctionsevier Inc.and the development stages (e.g., light
chain rearrangement, somatic hypermu-
tation status) would shed some lights on
how ATMIN executes tumor suppressor
function and how it is related to ATM func-
tion in B cells.
Somatic mutations of ATM are found in
a broad spectrum of human cancers,
whereas tumor-specific lesions of ATMIN
have not been reported in human cancers
so far. Nevertheless, given its role in DNA
repair and tumor suppression reported
by Loizou et al. (2011), ATMIN may also
serve as a suppressor of human tumor
development and, as such, a potential
target for therapeutic intervention. The
study by Loizou et al. (2011) provides
a valuable framework for future studies
aiming at the molecular mechanism by
which ATMIN and ATM promote DNA
repair and suppress tumor formation.
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